Recent news on

Abbott's novel psoriasis biologic shows promise  -  May 10, 2007
In-PharmaTechnologist.com,Amevive (alefacept), the first biologic treatment approved for treating moderate to severe psoriasis, Enbrel (etanercept), and Raptiva (efalizumab).

XOMA Executives to Present at BIO2007 Convention, Rodman & Renshaw ...  -  May 8, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono SA) to treat

XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes  -  Apr 12, 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono SA) to treat

Genentech Announces Positive Results from a Phase IV Study of ...  -  Feb 9, 2007
Drug Newswire (press release),Raptiva(R) (efalizumab) is a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of

NEWS RELEASE  -  Feb 6, 2007
Financial News USA (press release),Genentech, Inc. (NYSE: DNA) recently announced results from a Phase IV study of Raptiva® (efalizumab) that showed statistically significant improvement in

Genentech Announces Positive Results from a Phase IV Study of ...  -  Feb 2, 2007
Earthtimes.org2 -- Genentech, Inc. today announced results from a Phase IV study of Raptiva(R) (efalizumab) that showed statistically significant improvement in patients

XOMA to Present At Two Investor Conferences in February  -  Feb 9, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

Funding can depend on where you live  -  Feb 5, 2007
ic Wales,Efalizumab at a cost of £9000 a year for the treatment of Guillian Barre syndrome. Dr Martin Duerden, medical director of Conwy LHB, said, “Many new drugs

AAD: Raptiva Helps in Psoriasis of Hands and Feet  -  Feb 2, 2007
MedPage Today,2 -- A 12-week course of Raptiva (efalizumab) significantly improved chronic severe plaque psoriasis of the hands and feet, researchers here reported today.

XOMA and Schering-Plough Add New Programs to Antibody Collaboration  -  18 Jan 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

XOMA Initiates Clinical Trial of NEUPREX At Harvard Medical School ...  -  Jan 10, 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

XOMA Announces Pre-Clinical and Clinical Progress On HCD122  -  Dec 11, 2006
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

XOMA Reports Third Quarter 2006 Results  09 Nov 2006
...diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... -PrimeZone (press release), XOMA Designated as a Subcontractor in 5-Year NIAID Effort to ...  Nov 7, 2006
...diseases. XOMA has royalty interests in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... -Market Wire (press release) XOMA Receives European Certification To Manufacture  Nov 7, 2006
...diseases. XOMA has royalty interests in RAPTIVA (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... -Pharmaceutical Online (press release), 24-Week Clear Study Results Confirm Sustained Efficacy And Safety ...  Oct 31, 2006
4Lebwohl M. et al., Efficacy and Safety of efalizumab in patients with high body weight: pooled results from randomized phase III trials, Summer AAD 2005 ... -PipelineReview.com (press release), 24-Week Clear Study Results Confirm Sustained Efficacy and Safety ...  Oct 31, 2006
Raptiva(R) (efalizumab) is a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T ... -DG News Genentech Earnings: Lucentis Strong, Oncology Weakening  Oct 11, 2006
Products posting higher US sales than in the previous quarter included Xolair (omalizumab) at $107 million, Raptiva (efalizumab) at $23 million and Avastin ... -BioWorld Online, Genentech Announces Third Quarter 2006 Results  Oct 10, 2006
2005. -- US sales of RAPTIVA® (efalizumab) increased 10 percent to $23 million, from $21 million in the third quarter of 2005. ... -Yahoo! News (press release) Genentech Announces Third Quarter 2006 Results  Oct 10, 2006
2005. US sales of RAPTIVA® (efalizumab) increased 10 percent to $23 million, from $21 million in the third quarter of 2005. US ... -PharmaLive.com (press release), XOMA Announces Development Plan for XOMA 629 in Acne ...  Sep 8, 2006
...diseases. XOMA has royalty interests in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... -PipelineReview.com

XOMA Announces Pre-Clinical and Clinical Progress On HCD122  -  Dec 11, 2006
Primenewswire (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

XOMA to Present At Piper Jaffray's 18th Annual Health Care ...  -  Nov 29, 2006
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

NICE, options for the treatment of psoriasis and psoriatic ...  Aug 9, 2006
Health and Clinical Excellence ) has developed guidance on the use within the NHS in England and Wales of Etanercept ( Enbrel ) and Efalizumab ( Raptiva ) for ... -Xagena.it

OINTMENT MORE EFFECTIVE THAN RECENTLY NICE-APPROVED BIOLOGICS ...  Aug 10, 2006
1703 patients, demonstrated that 56%, 59% and 74% improved by 50% or more after 12 weeks in patients treated with alefacept, efalizumab and etanercept ... -ITNews

XOMA Unveils Strategy, Provides Update on NEUPREX(R); European ...  Aug 15, 2006
...diseases. XOMA has royalty interests in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... -Genetic Engineering News

Combined ointment effective for psoriasis  Aug 11, 2006
...that 56 percent, 59 percent and 74 percent improved by 50 percent or more after 12 weeks in patients treated with alefacept, efalizumab and etanercept ... -United Press International

XOMA Announces August 9 Conference Call and Webcast Discussion of ...  Jul 28, 2006
...diseases. XOMA has royalty interests in RAPTIVA(R)(efalizumab), a monoclonal antibody product marketed worldwide (byGenentech, Inc. ... -Finanzen.net

Your health  Aug 3, 2006
...guidelines from the National Institute for Health and Clinical Excellence (NICE) on the use of two key treatments, called etanercept and efalizumab, is sure to ... -Sur

Backing For The Use Of Advanced Biological Therapies To Treat ...  Jul 28, 2006
Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult ... -Medical News Today

NICE Gives Backing For The Use Of Advanced Biological Therapies To ...  Jul 31, 2006
Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat ... -Medical News Today

XOMA Reports Second Quarter 2006 Results  Aug 9, 2006
XOMA has royalty interests in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech and Serono, SA) to treat moderate-to ... -PharmaLive.com

NICE supports application of advanced biological therapies as ...  Jul 27, 2006
...and Clinical Excellence (NICE) has brought out guidance to effectively use biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to help ... -MedIndia

UCB: Cimzia making good progress  Jul 20, 2006
Enbrel (etanercept), Johnson & Johnson's/Schering-Plough's Remicade (infliximab), Biogen Idec's Amevive (alefacept) and Serano/Genentech's Raptiva (efalizumab ... -Pharmaceutical Business Review

Compelling Evidence Of Raptiva 12-Week Clear Trial Data In ...  Jun 22, 2006
The incidence of serious adverse events affecting the skin was 2.5% among efalizumab-treated patients and 2.3% among placebo-treated patients. ... -PipelineReview.com

Genentech Announces Second Quarter 2006 Results  Jul 11, 2006
2005. -- US sales of RAPTIVA® (efalizumab) increased 5 percent to $22 million, from $21 million in the second quarter of 2005. ... -Yahoo! News

Genentech Announces Second Quarter 2006 Results  Jul 11, 2006
2005. -- US sales of RAPTIVA(R) (efalizumab) increased 5 percent to $22 million, from $21 million in the second quarter of 2005. ... -PR Newswire



XOMA Reports First Quarter 2006 Results  May 10, 2006
XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. ... - Genetic Engineering News

XOMA Announces May 11 Conference Call and Webcast Discussion of ...  May 4, 2006
...diseases. XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. ... - Genetic Engineering News

Psoriasis: now he’s happy in his skin  Apr 28, 2006
...decides whether a drug works and if it’s worth spending NHS money on, decided that providing two of these biologic drugs — Raptiva (efalizumab) and Enbrel ... - Times Online





Genentech Announces Vice President Appointments in Commercial ...  11 Apr 2006
In this role, Anderson will be responsible for leading the sales and marketing activities for RAPTIVA® (efalizumab), Xolair® (Omalizumab), Rituxan ... - Yahoo! News

Efalizumab (Raptiva) Appears Safe for Up to 3 years of Psoriasis ...  Mar 9, 2006
SAN FRANCISCO, CA -- March 9, 2006 -- Efalizumab (Raptiva) appears to be safe for up to 3 years of continuous weekly therapy for chronic moderate to severe ... - DG News

Use of the Existing Cytokine Therapeutics in Inflammatory ...  Mar 31, 2006
...competition from drugs that offer alternative approaches to the treatment of inflammatory disease, including the T-cell modulators efalizumab and alefacept and ... - International News Service

XOMA Reports 2005 Results; Significant Revenue Growth and Other ...  Mar 8, 2006
XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. ... - International News Service

XOMA Announces Successful Exchange Offer With A Tender of 100% of ...  Feb 9, 2006
XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. ... - Genetic Engineering News,

Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ...  Feb 1, 2006
...competition from drugs that offer alternative approaches to the treatment of inflammatory disease, including the T-cell modulators efalizumab and alefacept and ... - Genetic Engineering News,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional